• DNTH312 is an internally developed bifunctional fusion protein targeting potent inhibition of active C1s (aC1s) and BAFF/APRIL, two validated pathways with complementary disease modifying mechanisms
  • DNTH312 demonstrated comparable in vitro potency and aC1s inhibition to claseprubart, with a comparable non-human primate (NHP) half-life
  • DNTH312 showed similar depth of Ig reductions vs. povetacicept following a single dose in NHPs
  • By building on claseprubart’s best-in-class profile, DNTH312 strengthens Dianthus’ leadership in neuromuscular disease, while expanding into additional autoimmune diseases where both B cell modulation and Classical Pathway inhibition could provide additional benefits to more patients
  • DNTH312 aims to be Phase 1 ready by YE’27